| News Updates |
 |
Merck to let generic makers produce low-cost HIV prevention pill
TRTWorld | July 24, 2026
|
|
Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development
MERCK | July 24, 2026
|
|
Once Weekly Oral HIV Regimen Maintains Suppression Through Week 48
DrugTopics | July 22, 2026
|
|
In ongoing trials, twice-yearly HIV prevention drug saw just one case
devex | July 21, 2026
|
|
Investigational Once-weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who...
MERCK | July 21, 2026
|
|
Two- vs Three-Drug Combo for Immune Recovery in HIV Infection: No Clear Winner
Medscape | July 13, 2026
|
|
Lenacapavir offers extraordinary promise but communication will decide its impact
Daily Maverick | July 13, 2026
|
|
The cost of HIV drugs for Medicare is projected to skyrocket by 2035
CIDRAP | July 7, 2026
|
|
Doxycycline PEP Shows Limited Efficacy for Gonorrhea Prevention
IDA | July 6, 2026
|
|
New HIV vaccine successfully generates broadly neutralizing antibodies in primates
News-Medical | July 6, 2026
|
|
FDA Grants Priority Review for Dolutegravir in Newborns With HIV
Contagion Live | July 5, 2026
|
|
New HIV Drugs & What’s Coming Down the Pike
IDSE | July 3, 2026
|
|
What You Should Know About Idvynso for HIV
IDSE | June 30, 2026
|
|
FDA Approves Idvynso Combination Pill
POZ | June 29, 2026
|
|
Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV
Merck | June 29, 2026
|
|
National HIV Testing Day Highlights Expanding PrEP, PEP Access, Persistent Barriers
AJMC | June 27, 2026
|
|
AIDSVu Releases 2025 PrEP Data Showing Record High PrEP Use, Though Persistent Gaps in HIV Prevention Access and Uptake Remain
AIDSVu | June 24, 2026
|
|
MSF at Pride: Gilead must increase global access to HIV prevention medicine
Doctors Without Borders | June 24, 2026
|
|
Few People With HIV on Medicare Are Using Long-Acting Treatment
POZ | June 24, 2026
|
|
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly...
Gilead | June 8, 2026
|
|
Switching or Simplifying Antiretroviral Therapy
National HIV Curriculum | Updated: June 3, 2026
|
|
New HIV treatment could enable people to safely stop daily medication
Imperial.ac.uk | May 27, 2026
|
|
Ritonavir
HIV.gov | May 26, 2026
|
|
Antiretroviral Medications and Initial Therapy
National HIV Curriculum | Updated May 15, 2026
|
|
HIV PrEP Medications and Dosing Options
IDEA | May 15, 2026
|
|
Antiretroviral Medications and Initial Therapy
National HIV Curriculum | May 15, 2026
|
|
Inside the ‘miracle’ drug rollout that could end Aids
Independent | May 6, 2026
|
| |
|
